Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.

ABSTRACT: Breast cancer bone metastases are common and incurable. Tumoral integrin β3 (β3) expression is induced through interaction with the bone microenvironment. Although β3 is known to promote bone colonization, its functional role during therapy of established bone metastases is not known. We found increased numbers of β3⁺ tumor cells in murine bone metastases after docetaxel chemotherapy. β3⁺ tumor cells were present in 97% of post-neoadjuvant chemotherapy triple-negative breast cancer patient samples (n = 38). High tumoral β3 expression was associated with worse outcomes in both pre- and postchemotherapy triple-negative breast cancer groups. Genetic deletion of tumoral β3 had minimal effect in vitro, but significantly enhanced in vivo docetaxel activ

SUBMITTER: Fox GC 

PROVIDER: S-EPMC8442608 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature